The Global Acute Repetitive Seizures Market: ARS poses a risk of hospitalization and/or evolution into status epilepticus, a life-threatening seizure emergency, which underscores the need for early, effective management.

Published Date: 11/05/2021

The Global Acute Repetitive Seizures Market size was estimated at USD 487.76 Million in 2020 and is expected to reach USD 2640 Million registering a CAGR of 46.7% over the forecast period.

A seizure, formally known as an epileptic seizure, is a period of symptoms due to abnormally excessive or synchronous neuronal activity in the brain. Outward effects vary from uncontrolled shaking movements involving much of the body with loss of consciousness (tonic-clonic seizure), to shaking movements involving only part of the body with variable levels of consciousness (focal seizure), to a subtle momentary loss of awareness (absence seizure). Most of the time these episodes last less than 2 minutes and it takes some time to return to normal. Loss of bladder control may occur.

Seizures may be provoked and unprovoked. Provoked seizures are due to a temporary event such as low blood sugar, alcohol withdrawal, low blood sodium, fever, brain infection, or concussion, Unprovoked seizures occur without a known or fixable cause such that ongoing seizures are likely. Unprovoked seizures may be triggered by stress or sleep deprivation. Diseases of the brain, where there has been at least one seizure and a long term risk of further seizures, are collectively known as epilepsy. Conditions that look like epileptic seizures but are not include: fainting, nonepileptic psychogenic event and tremor.

High unmet clinical demand for patients, as well as caregivers, and accessibility of progressive product pipeline are some of the main factors anticipated to push industry development. Drug therapy is operative for many of the patients suffering from cluster seizures. Though, there are an important numeral of treatment challenges and unmet medical demand such as drug induced seizures, adverse reactions, and lack of ant epileptogenic agents that can prevent growth of seizures and its comorbidities.
The acute repetitive seizures market is presently led by generic drugs which mainly comprise oral benzodiazepines (diazepam and lorazepam). Rectal diazepam is the single approved drug for usage in U.S. and buccal midazolam in European Union. Other medicines, for instance, midazolam (intramuscular, buccal, intranasal,), diazepam (intramuscular and oral), progesterone and lorazepam (intranasal, oral, sublingual) and are mainly used off label. The industry is anticipated to be combined with some major businesses and high market chunk in terms of revenue.

Furthermore, in an attempt to curb healthcare expenditure, governments are making continuous efforts to reduce hospital stays and on-site treatment costs via outpatient care models, such as clinic and home healthcare. Emerging economies like India and China, are increasingly implementing such healthcare reform, which is expected to propel the growth of acute repetitive seizures market. There are several routes of drug administration; out of which, nasal route is the most preferred over others, such as buccal, rectal, and parenteral. The buccal route is preferred by caregivers and parents for children suffering from pediatric seizures since medication can be administered even outside the hospital.